search

Active clinical trials for "Choroidal Neovascularization"

Results 61-70 of 174

Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization...

Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)

Open-label Multicenter, Phase I/II Study comprising three phases (single dose, multiple dose and extension phase), Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD).

Completed10 enrollment criteria

Photodynamic Therapy in Occult-Only Lesions (POOL)

Age-Related Macular Degeneration

Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye. Verteporfin may stabilize the disease, by closing the blood vessels. This study will assess the efficacy and safety of verteporfin in patients with occult only lesions.

Completed7 enrollment criteria

Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary...

Wet Age-Related Macular Degeneration

This study evaluates the tolerability and safety of 3 months treatment with PTK787 tablets given daily. It also explores the efficacy of the compound in patients with wet age-related macular edema. In Cohort 1 verteporfin/PDT is the active control. The protocol was amended to reflect the current standard of care for AMD. As a result, ranibizumab is the active control for Cohort 2.

Completed8 enrollment criteria

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular...

Age-related Macular DegenerationNeovascular Age-related Macular Degeneration1 more

This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.

Completed20 enrollment criteria

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular...

Age-related Macular DegenerationNeovascular Age-related Macular Degeneration1 more

This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.

Completed18 enrollment criteria

An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare...

Choroidal NeovascularizationMacular Edema3 more

The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.

Completed14 enrollment criteria

Efficacy and Safety of RTH258 Versus Aflibercept - Study 1

Neovascular Age-Related Macular DegenerationChoroidal Neovascularization

The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.

Completed14 enrollment criteria

Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization...

Pathological Myopia

This study is designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (PM).

Completed9 enrollment criteria

VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)

MyopiaPathological

VEGF Trap-Eye will be tested for safety and efficacy in patients with vision loss due to choroidal neovascularization secondary to pathologic myopia. This will be a placebo-controlled trial. 3 out of 4 patients will receive an injection of VEGF Trap-Eye into the affected eye (and repeated injections if required), and 1 out of 4 patients will receive a sham injection requiring no needle stick, but making the patient unaware of whether or not he received active treatment. Outcome of the two treatment groups will be compared after 24 weeks. From week 24, sham patients may receive active treatment. Total duration of the study will be 48 weeks.

Completed43 enrollment criteria

A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due...

Neovascular Age-related Macular Degeneration

This study is designed to assess the efficacy and safety of multiple intravitreal injection of KH902 in patients with CNV due to AMD.

Completed18 enrollment criteria
1...678...18

Need Help? Contact our team!


We'll reach out to this number within 24 hrs